Desmethylclozapine: Difference between revisions
Content deleted Content added
m clean up using AWB |
Changing short description from "Chemical compound" to "Active metabolite of the drug clozapine" |
||
| (22 intermediate revisions by 15 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Active metabolite of the drug clozapine}} |
|||
{{Drugbox |
{{Drugbox |
||
| IUPAC_name = 8-chloro-11-piperazin-1-yl-5''H''-dibenzo[b,e][1,4]diazepine |
| IUPAC_name = 8-chloro-11-piperazin-1-yl-5''H''-dibenzo[b,e][1,4]diazepine |
||
| Line 30: | Line 31: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=17 | H=17 | Cl=1 | N=4 |
| C=17 | H=17 | Cl=1 | N=4 |
||
| molecular_weight = 312.80 g/mol |
|||
| smiles = Clc1ccc2Nc4ccccc4C(=N\c2c1)/N3CCNCC3 |
| smiles = Clc1ccc2Nc4ccccc4C(=N\c2c1)/N3CCNCC3 |
||
}} |
}} |
||
'''''N''-Desmethylclozapine''' ('''NDMC'''), or '''norclozapine''', is a major [[activity (chemistry)|active]] [[metabolite]] of the [[atypical antipsychotic]] [[drug]] [[clozapine]].<ref name="pmid2057995">{{cite journal |vauthors=Lovdahl MJ, Perry PJ, Miller DD | title = The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography | journal = Therapeutic Drug Monitoring | volume = 13 | issue = 1 | pages = 69–72 |date=January 1991 | pmid = 2057995 | doi = 10.1097/00007691-199101000-00010 |
'''''N''-Desmethylclozapine''' ('''NDMC'''), or '''norclozapine''', is a major [[activity (chemistry)|active]] [[metabolite]] of the [[atypical antipsychotic]] [[drug]] [[clozapine]].<ref name="pmid2057995">{{cite journal |vauthors=Lovdahl MJ, Perry PJ, Miller DD | title = The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography | journal = Therapeutic Drug Monitoring | volume = 13 | issue = 1 | pages = 69–72 |date=January 1991 | pmid = 2057995 | doi = 10.1097/00007691-199101000-00010}}</ref><ref name="pmid2658370">{{cite journal |vauthors=Bablenis E, Weber SS, Wagner RL | title = Clozapine: a novel antipsychotic agent | journal = DICP: The Annals of Pharmacotherapy | volume = 23 | issue = 2 | pages = 109–15 |date=February 1989 | pmid = 2658370 | doi = 10.1177/106002808902300201| s2cid = 36582093 }}</ref> Unlike clozapine, it possesses [[intrinsic activity]] at the [[D2 receptor|D<sub>2</sub>]]/[[D3 receptor|D<sub>3</sub> receptor]]s, and acts as a weak [[partial agonist]] at these sites similarly to [[aripiprazole]] and [[bifeprunox]].<ref name="pmid16135699">{{cite journal |vauthors=Burstein ES, Ma J, Wong S, etal | title = Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 315 | issue = 3 | pages = 1278–87 |date=December 2005 | pmid = 16135699 | doi = 10.1124/jpet.105.092155 | s2cid = 2247093 }}</ref> Notably, NDMC has also been shown to act as a [[potency (pharmacology)|potent]] and [[intrinsic activity|efficacious]] [[agonist]] at the [[M1 receptor|M<sub>1</sub>]] and [[delta-opioid receptor|δ-opioid receptor]]s, unlike clozapine as well.<ref name="pmid15258717">{{cite journal |vauthors=Weiner DM, Meltzer HY, Veinbergs I, etal | title = The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine | journal = Psychopharmacology | volume = 177 | issue = 1–2 | pages = 207–16 |date=December 2004 | pmid = 15258717 | doi = 10.1007/s00213-004-1940-5 | s2cid = 1024531 }}</ref><ref name="pmid15900318">{{cite journal |vauthors=Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY | title = N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors | journal = Neuropsychopharmacology | volume = 30 | issue = 11 | pages = 1986–95 |date=November 2005 | pmid = 15900318 | doi = 10.1038/sj.npp.1300768 | doi-access = free }}</ref><ref name="pmid19239909">{{cite journal |vauthors=Olianas MC, Dedoni S, Ambu R, Onali P | title = Agonist activity of N-desmethylclozapine at delta-opioid receptors of human frontal cortex | journal = European Journal of Pharmacology | volume = 607 | issue = 1–3 | pages = 96–101 |date=April 2009 | pmid = 19239909 | doi = 10.1016/j.ejphar.2009.02.025 }}</ref> It was hypothesized that on account of these unique actions, NDMC might underlie the clinical superiority of clozapine over other antipsychotics. However, [[clinical trial]]s found NMDC itself ''ineffective'' in the treatment of [[schizophrenia]].<ref name="pmid18973393">{{cite journal |vauthors=Bishara D, Taylor D | title = Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability | journal = Drugs | volume = 68 | issue = 16 | pages = 2269–92 | year = 2008 | pmid = 18973393 | doi = 10.2165/0003495-200868160-00002| s2cid = 42020114 }}</ref><ref name="pmid19483482">{{cite journal |vauthors=Mendoza MC, Lindenmayer JP | title = N-desmethylclozapine: is there evidence for its antipsychotic potential? | journal = Clinical Neuropharmacology | volume = 32 | issue = 3 | pages = 154–7 | year = 2009 | pmid = 19483482 | doi = 10.1097/WNF.0b013e31818d46f5 | s2cid = 24544110 }}</ref> This may be because it possesses relatively low D<sub>2</sub>/D<sub>3</sub> occupancy compared to 5-HT<sub>2</sub> (<15% versus 64–79% at a dose of 10–60 mg/kg [[subcutaneous injection|s.c.]] in animal studies).<ref name="pmid17164815">{{cite journal |vauthors=Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S | title = Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies | journal = Neuropsychopharmacology | volume = 32 | issue = 7 | pages = 1540–9 |date=July 2007 | pmid = 17164815 | doi = 10.1038/sj.npp.1301279 | doi-access = free }}</ref> Albeit not useful in the treatment of [[Schizophrenia#Positive and negative symptoms|positive symptom]]s on its own, it cannot be ruled out that NDMC may contribute to the efficacy of clozapine on [[cognitive deficit|cognitive]] and/or [[Schizophrenia#Positive and negative symptoms|negative symptom]]s.<ref name="pmid18973393"/> |
||
== See also == |
== See also == |
||
* [[Clozapine]] |
* [[Clozapine]] |
||
* [[DHA-clozapine]] |
* [[DHA-clozapine]] |
||
* [[Loxapine]] |
|||
== References == |
== References == |
||
{{ |
{{reflist|30em}} |
||
{{Reflist|2}} |
|||
{{Antipsychotics}} |
{{Antipsychotics}} |
||
{{Histamine receptor modulators}} |
|||
{{Cholinergics}} |
|||
{{Muscarinic acetylcholine receptor modulators}} |
|||
{{Histaminergics}} |
|||
{{Opioid receptor modulators}} |
|||
{{Opioidergics}} |
|||
{{Piperazines}} |
|||
{{Tricyclics}} |
{{Tricyclics}} |
||
[[Category:Antipsychotics]] |
[[Category:Antipsychotics]] |
||
[[Category:Chloroarenes]] |
[[Category:Chloroarenes]] |
||
[[Category:Delta-opioid agonists]] |
[[Category:Delta-opioid receptor agonists]] |
||
[[Category:Dibenzodiazepines]] |
[[Category:Dibenzodiazepines]] |
||
[[Category:Mu-opioid agonists]] |
[[Category:Mu-opioid receptor agonists]] |
||
[[Category: |
[[Category:Muscarinic agonists]] |
||
[[Category:1-Piperazinyl compounds]] |
|||
[[Category:Human drug metabolites]] |
[[Category:Human drug metabolites]] |
||
{{ |
{{Analgesic-stub}} |
||
Revision as of 23:54, 28 October 2023
 | |
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.164.220 |
| Chemical and physical data | |
| Formula | C17H17ClN4 |
| Molar mass | 312.80 g·mol−1 |
| 3D model (JSmol) | |
| |
N-Desmethylclozapine (NDMC), or norclozapine, is a major active metabolite of the atypical antipsychotic drug clozapine.[1][2] Unlike clozapine, it possesses intrinsic activity at the D2/D3 receptors, and acts as a weak partial agonist at these sites similarly to aripiprazole and bifeprunox.[3] Notably, NDMC has also been shown to act as a potent and efficacious agonist at the M1 and δ-opioid receptors, unlike clozapine as well.[4][5][6] It was hypothesized that on account of these unique actions, NDMC might underlie the clinical superiority of clozapine over other antipsychotics. However, clinical trials found NMDC itself ineffective in the treatment of schizophrenia.[7][8] This may be because it possesses relatively low D2/D3 occupancy compared to 5-HT2 (<15% versus 64–79% at a dose of 10–60 mg/kg s.c. in animal studies).[9] Albeit not useful in the treatment of positive symptoms on its own, it cannot be ruled out that NDMC may contribute to the efficacy of clozapine on cognitive and/or negative symptoms.[7]
See also
References
- ^ Lovdahl MJ, Perry PJ, Miller DD (January 1991). "The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography". Therapeutic Drug Monitoring. 13 (1): 69–72. doi:10.1097/00007691-199101000-00010. PMID 2057995.
- ^ Bablenis E, Weber SS, Wagner RL (February 1989). "Clozapine: a novel antipsychotic agent". DICP: The Annals of Pharmacotherapy. 23 (2): 109–15. doi:10.1177/106002808902300201. PMID 2658370. S2CID 36582093.
- ^ Burstein ES, Ma J, Wong S, et al. (December 2005). "Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist". The Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1278–87. doi:10.1124/jpet.105.092155. PMID 16135699. S2CID 2247093.
- ^ Weiner DM, Meltzer HY, Veinbergs I, et al. (December 2004). "The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine". Psychopharmacology. 177 (1–2): 207–16. doi:10.1007/s00213-004-1940-5. PMID 15258717. S2CID 1024531.
- ^ Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY (November 2005). "N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors". Neuropsychopharmacology. 30 (11): 1986–95. doi:10.1038/sj.npp.1300768. PMID 15900318.
- ^ Olianas MC, Dedoni S, Ambu R, Onali P (April 2009). "Agonist activity of N-desmethylclozapine at delta-opioid receptors of human frontal cortex". European Journal of Pharmacology. 607 (1–3): 96–101. doi:10.1016/j.ejphar.2009.02.025. PMID 19239909.
- ^ a b Bishara D, Taylor D (2008). "Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability". Drugs. 68 (16): 2269–92. doi:10.2165/0003495-200868160-00002. PMID 18973393. S2CID 42020114.
- ^ Mendoza MC, Lindenmayer JP (2009). "N-desmethylclozapine: is there evidence for its antipsychotic potential?". Clinical Neuropharmacology. 32 (3): 154–7. doi:10.1097/WNF.0b013e31818d46f5. PMID 19483482. S2CID 24544110.
- ^ Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (July 2007). "Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies". Neuropsychopharmacology. 32 (7): 1540–9. doi:10.1038/sj.npp.1301279. PMID 17164815.
 | This analgesic-related article is a stub. You can help Wikipedia by expanding it. |